Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
181.80 EUR | -0.25% |
|
-4.01% | -5.41% |
02-13 | UCB?s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market | CI |
02-12 | UCB's BIMZELX Demonstrates Sustained Disease Control In Hidradenitis Suppurativa | RE |
Capitalization | 34.58B 36.23B 32.63B 28.72B 51.38B 3,146B 56.9B 388B 144B 1,313B 136B 133B 5,486B | P/E ratio 2024 * |
63x | P/E ratio 2025 * | 35.4x |
---|---|---|---|---|---|
Enterprise value | 35.98B 37.71B 33.96B 29.89B 53.47B 3,275B 59.22B 403B 150B 1,367B 141B 139B 5,709B | EV / Sales 2024 * |
6.11x | EV / Sales 2025 * | 5.12x |
Free-Float |
61.3% | Yield 2024 * |
0.77% | Yield 2025 * | 0.79% |
Last Transcript: UCB
1 day | -0.05% | ||
1 week | -3.75% | ||
Current month | -3.21% | ||
1 month | -3.80% | ||
3 months | +2.33% | ||
6 months | +21.07% | ||
Current year | -5.23% |







Manager | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 66 | 2014-12-31 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 58 | 2020-06-30 |
Chief Tech/Sci/R&D Officer | 66 | 2018-12-31 |
Director | Title | Age | Since |
---|---|---|---|
Director/Board Member | 54 | 2011-12-31 | |
Director/Board Member | 66 | 2014-12-31 | |
Director/Board Member | 55 | 2014-04-23 |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-0.05% | -3.75% | +93.65% | +114.45% | 36.23B | ||
+2.14% | -2.41% | -7.11% | -4.76% | 79.64B | ||
+1.90% | +17.90% | +40.69% | +56.37% | 58.52B | ||
-0.81% | -3.66% | -37.32% | -34.79% | 20.1B | ||
-1.85% | -5.48% | +327.83% | +820.50% | 14.74B | ||
+0.59% | +3.10% | +21.50% | +3.82% | 13.63B | ||
-0.19% | +0.55% | +68.96% | +122.33% | 13.58B | ||
+0.67% | +2.13% | -26.95% | -28.18% | 12.36B | ||
+0.98% | +2.67% | +10.26% | -43.17% | 12.05B | ||
-0.13% | -1.56% | +26.20% | +67.20% | 10.14B | ||
Average | +0.33% | -1.56% | +51.77% | +107.38% | 27.1B | |
Weighted average by Cap. | +0.96% | -2.09% | +39.02% | +73.74% |
2024 * | 2025 * | |
---|---|---|
Net sales | 5.89B 6.17B 5.56B 4.89B 8.75B 536B 9.69B 66.02B 24.48B 224B 23.13B 22.67B 934B | 6.85B 7.17B 6.46B 5.69B 10.17B 623B 11.27B 76.75B 28.46B 260B 26.88B 26.35B 1,086B |
Net income | 629M 659M 594M 523M 935M 57.26B 1.04B 7.05B 2.62B 23.9B 2.47B 2.42B 99.83B | 963M 1.01B 909M 800M 1.43B 87.6B 1.58B 10.79B 4B 36.56B 3.78B 3.71B 153B |
Net Debt | 1.41B 1.48B 1.33B 1.17B 2.09B 128B 2.32B 15.79B 5.85B 53.48B 5.53B 5.42B 223B | 481M 504M 454M 399M 715M 43.75B 791M 5.39B 2B 18.26B 1.89B 1.85B 76.29B |
Date | Price | Change | Volume |
---|---|---|---|
25-02-18 | 181.80 € | -0.25% | 26,535 |
25-02-17 | 182.25 € | +1.00% | 147,453 |
25-02-14 | 180.45 € | -3.58% | 235,170 |
25-02-13 | 187.15 € | -1.68% | 181,614 |
25-02-12 | 190.35 € | +0.50% | 128,193 |
Real-time Euronext Bruxelles, February 18, 2025 at 06:04 am
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- UCB Stock

MarketScreener is also available in this country: United States.
Switch edition